The increasing use of polymyxins 1 in addition to the dissemination of plasmid-borne colistin resistance threatens to cause a serious breach in our last line of defence against multidrugresistant Gram-negative pathogens, and heralds the emergence of truly pan-resistant infections. Colistin resistance often arises through covalent modification of lipid A with cationic residues such as phosphoethanolamine-as is mediated by Mcr-1 (ref.
2)-which reduce the affinity of polymyxins for lipopolysaccharide 3 . Thus, new strategies are needed to address the rapidly diminishing number of treatment options for Gramnegative infections 4 . The difficulty in eradicating Gramnegative bacteria is largely due to their highly impermeable outer membrane, which serves as a barrier to many otherwise effective antibiotics 5 . Here, we describe an unconventional screening platform designed to enrich for non-lethal, outermembrane-active compounds with potential as adjuvants for conventional antibiotics. This approach identified the antiprotozoal drug pentamidine 6 as an effective perturbant of the Gram-negative outer membrane through its interaction with lipopolysaccharide. Pentamidine displayed synergy with antibiotics typically restricted to Gram-positive bacteria, yielding effective drug combinations with activity against a wide range of Gram-negative pathogens in vitro, and against systemic Acinetobacter baumannii infections in mice. Notably, the adjuvant activity of pentamidine persisted in polymyxinresistant bacteria in vitro and in vivo. Overall, pentamidine and its structural analogues represent unexploited molecules for the treatment of Gram-negative infections, particularly those having acquired polymyxin resistance determinants.
Previous work by our group has shown that Escherichia coli becomes susceptible to vancomycin during periods of cold stress 7 . Paradoxically, this phenotype could be reversed through inactivation of the genes involved in outer membrane biosynthesis, particularly those required for the core oligosaccharide (core OS) of lipopolysaccharide (LPS) 8 . Given that genetic lesions in nonessential outer membrane biosynthesis often sensitize Gramnegative species to canonical Gram-positive antibiotics 9 , we reasoned that screening for vancomycin antagonism at low temperature would yield non-lethal molecules that perturb the outer membrane. As a proof of principle, a comparative analysis of E. coli gene deletion mutants that resisted the action of vancomycin at 15°C, and those that showed enhanced sensitivity to the Gram-positive antibiotics erythromycin, novobiocin and/or rifampicin at 37°C, revealed many common genes coding for functions in outer membrane biosynthesis ( Fig. 1a and Supplementary Table 1 ). In agreement with this observation, an analysis of all gene deletion mutants displaying vancomycin resistance at 15°C revealed a significant enrichment for genes encoding functions in LPS and carbohydrate biosynthesis, as well those responsible for lipid metabolism and transport ( Fig. 1b and Supplementary Table 2 ), all of which are essential to maintain outer membrane integrity. Together, these results show that screening for vancomycin antagonism at low temperature is capable of enriching for the gene products necessary for outer membrane biosynthesis.
We subsequently leveraged these observations to develop a unique small-molecule screening platform to detect non-lethal compounds that perturb outer membrane architecture. Indeed, molecules that preferentially target the outer membrane have long been sought as antibiotic adjuvants 10 , but none have successfully entered the clinic 11 . Importantly, the sensitivity and specificity of this cold-dependent phenotype in capturing an outer-membranecentric target list renders it a powerful platform for drug screening, as conventional antibiotic sensitization screens often capture large numbers of hit compounds with extraneous activities (Supplementary Table 1 ).
We thus performed a screen of 1,440 previously approved drugs for those that suppressed the activity of vancomycin against E. coli at 15°C ( Supplementary Table 3 ). Only three active compounds were identified, highlighting the specificity of this screening approach. We pursued these actives by assessing their ability to suppress vancomycin activity at 15°C in a dose-dependent manner against wildtype E. coli, and then counter-screened for vancomycin suppression in E. coli expressing mcr-1. Pentamidine, used for the treatment of pneumocystis pneumonia and West African trypanosomiasis, displayed the most potent suppression of vancomycin activity against wild-type E. coli ( Fig. 1c and Supplementary Fig. 1 ), and was prioritized for further analysis. Interestingly, expression of mcr-1 did not impair the ability of pentamidine to suppress vancomycin activity at low temperature ( Fig. 1d ).
Consistent with an ability to suppress vancomycin activity, atomic force microscopy of pentamidine-treated E. coli revealed a dramatic effect on outer membrane structure at 37°C. The surface topography of pentamidine-treated cells was characterized by undulations on the order of 40 nm in amplitude, whereas untreated E. coli remained largely uniform ( Fig. 1e and Supplementary Fig. 2 ). Analysis of E. coli LPS following treatment with pentamidine at 37°C failed to show inhibition of core OS biosynthesis ( Supplementary Fig. 3a ), suggesting that pentamidine may directly associate with the outer membrane. Consistently, pentamidine resulted in enhanced release of LPS from the outer membrane of E. coli ( Supplementary  Fig. 3a ), similar to that previously observed with polymyxins 12 and other outer-membrane stressors 13 . Additionally, pentamidine failed to cause the release of periplasmic or cytoplasmic proteins, as did polymyxin B nonapeptide (PMBN) and a sub-inhibitory concentration of polymyxin B ( Supplementary Fig. 3b ), in agreement with previous work 14, 15 . Indeed, it has been shown that pentamidine displays high affinity for purified lipid A in vitro (dissociation constant K d of ∼120 nM) 16 , consistent with the aforementioned observations. Pentamidine has previously been reported to display a variety of activities depending on biological context. These include, for example, inhibition of both mitochondrial tRNA charging in Saccharomyces cerevisiae 17 , and group I intron ribozymes in Pneumocystis carinii and Candida albicans 18 . Additionally, pentamidine has been shown to inhibit undecaprenyl diphosphate synthase (UppS) from E. coli and Staphylococcus aureus in vitro, and bind purified DNA with low affinity 19 . Nevertheless, the idiosyncratic antagonism by pentamidine of growth inhibition by vancomycin at 15°C, as well as the outer-membrane perturbations upon pentamidine treatment at 37°C, strongly support a primary mechanism of action involving outer-membrane disruption in the specific context of a Gram-negative bacterium. Furthermore, we saw no enhanced activity of pentamidine (alone) against a strain of E. coli expressing a truncated LPS variant ( Supplementary Fig. 4 ), a finding inconsistent with the hypothesis that this molecule functioned through inhibition of an intracellular target.
Given its ability to disrupt outer-membrane architecture, we reasoned that pentamidine would act as an antibiotic adjuvant capable of sensitizing Gram-negative bacteria to antibiotics typically restricted to Gram-positive bacteria. Reminiscent of the ability of PMBN to potentiate large-molecular-weight antibiotics through electrostatic associations with lipid A (ref. 15 ), pentamidine potentiated the activity of Gram-positive antibiotics against E. coli at 37°C ( Fig. 2a ). Specifically, pentamidine synergized with rifampicin, novobiocin and erythromycin (fractional inhibitory concentration (FIC) index of ≤0.5; see Methods), all of which are hydrophobic, but not with the hydrophilic glycopeptide vancomycin. These data are consistent with antibiotic potentiation by PMBN, where synergy with hydrophobic molecules is generally more pronounced than that with hydrophilic molecules 20 . Additionally, pentamidine failed to significantly enhance the activity of low-molecular-weight antibiotics that can passively diffuse through the outer membrane, or gain access to the cytoplasm through membrane porins ( Supplementary Fig. 5a ). Pentamidine (μg ml −1 ) Figure 1 | A vancomycin antagonism screening platform identifies pentamidine. a, Venn diagram showing the number of gene deletion mutants that displayed sensitivity to novobiocin (blue), rifampicin (orange) and/or erythromycin (yellow) at 37°C, and/or resistance to vancomycin (grey) at 15°C. The E. coli gene deletion (Keio) collection was arrayed on solid LB medium containing sub-inhibitory concentrations of each antibiotic, and sensitivity or resistance was determined by analysing colony growth 35 . Bold numbers highlight the genes that displayed sensitivity to any combination of novobiocin, rifampicin or erythromycin, as well as resistance to vancomycin. Asterisks are used to differentiate between populations of genes, and relate to data shown in Supplementary Table 1 . b, Forty-one gene deletion mutants that displayed resistance to vancomycin at 15°C were classified based on gene ontology (GO), biosynthetic pathway or promoter activation, and statistical enrichment was calculated using EcoCyc Pathway Tools [37] [38] [39] . Enrichment was based on functional over-representation of the genes resulting in vancomycin resistance, using a Fisher's exact test to calculate P value. Calculations were performed in Pathway Tools using the enrichment analysis function without multiple hypothesis correction. The eight most statistically enriched, non-redundant GO, biosynthetic pathway and promoter activation classifications are shown. c, Chequerboard broth microdilution assay showing dose-dependent vancomycin suppression by pentamidine against wild-type E. coli grown at 15°C. Dark regions represent higher cell density. d, As in c, except cells were transformed with the pGDP2 plasmid containing mcr-1. The data in the chequerboard experiments in c and d are representative of at least two biological replicates. e, Atomic force microscopy of wild-type E. coli grown at 37°C to mid-log phase (OD of ∼0.5) in the presence of 25 µg ml −1 pentamidine. The white box (left) highlights the region scanned to obtain high-resolution topographical images of the cell surface (right). Scans are representative from two independent experiments.
To further investigate the ability of pentamidine to disrupt outermembrane integrity through association with LPS, we tested the effect of adding exogenous LPS into the growth medium. Adding increasing concentrations of purified E. coli LPS to growth medium abolished pentamidine-dependent potentiation of rifampicin in a dosedependent fashion ( Fig. 2b and Supplementary Fig. 5b ). As expected, the presence of exogenous LPS also suppressed the ability of PMBN to potentiate rifampicin ( Supplementary Fig. 5c ). Interestingly, both pentamidine and PMBN failed to potentiate rifampicin when cells were grown in the presence of high concentrations of Mg 2+ ( Supplementary Fig. 5d ), which promotes electrostatic interactions between adjacent LPS molecules 21 . These observations suggest that both adjuvants potentiate antibiotics through the disruption of lateral inter-LPS interactions. Consistent with this, pentamidine activated the PhoPQ two-component system, which is stimulated in Mg 2+ -limiting conditions, and upon challenge with cationic peptides 3, 22 (Fig. 2c and Supplementary Fig. 5e ).
To gain further insight into the specific location where pentamidine associates with LPS, we analysed the ability of pentamidine to potentiate rifampicin in E. coli mutants expressing truncated variants of core OS ( Fig. 2d and Supplementary Fig. 5f ). We observed that deeper truncations in core OS, or removal of core OS phosphate residues, resulted in more pronounced synergy, suggesting that pentamidine association with lipid A is a primary contributor to outer-membrane disorganization. Indeed, a model in which pentamidine disrupts lateral interactions between lipid A molecules was further supported through structure-function studies of pentamidine analogues. Specifically, we observed that both cationic amidine groups were essential for pentamidine activity (analogues 2 and 3), and that increasing the inter-amidine distance (analogues 4 and 8), increasing hydrophobicity (analogues 8 and 9) and decreasing molecular flexibility (analogue 9) proportionately increased rifampicin potentiation against E. coli (Table 1) .
To evaluate the spectrum of coverage by pentamidine against Gram-negative pathogens, we examined the in vitro activity of pentamidine in combination with rifampicin against a panel of clinical isolates. Pentamidine synergized with rifampicin against a wide phylogenetic distribution of antibiotic-resistant strains, including naturally polymyxin-resistant Serratia species ( Fig. 2e and Supplementary Table 4 ). The lack of potentiation against Pseudomonas aeruginosa may be rationalized by the presence of additional phosphate residues in core OS (ref. 23) , decreasing the access of pentamidine to lipid A. However, an explanation for the absence of potentiation in Proteus and Morganella species remains elusive. Indeed, all Serratia, Proteus and Morganella isolates tested were highly resistant to polymyxin B ( Supplementary Table 5 ). and E. coli ΔphoP (pink) were grown at 37°C to mid-log phase (OD of ∼0.5), and transcript levels of the PhoPQ-dependent gene mgtA (ref. 42) were quantified relative to the housekeeping gene rsmC using qRT-PCR. Data are means with standard error from two biological replicates. d, Pentamidinedependent potentiation of rifampicin against E. coli displaying various truncations in core OS. Cells were grown at 37°C and FIC indices were calculated using chequerboard broth microdilution assays as described in the Methods. Data are representative of at least two biological replicates. White letters indicate the Waa core OS biosynthetic gene that is responsible for addition of the corresponding residue. WaaY (pink) is necessary for the addition of phosphate to heptose II (pink). Loss of WaaP (*) prevents the addition of both core OS phosphates (*), as well as side-chain heptose III (*). Dark blue represents outer core OS; mid blue represents inner core OS; light blue represents 3-deoxy-D-manno-oct-2-ulosonic acid residues. e, Pentamidine-dependent potentiation of rifampicin against a spectrum of antibiotic-resistant Gram-negative clinical isolates using chequerboard broth microdilution assays. The FIC index cutoff defining synergy was set to ≤0.5. Blue shows members of the Xanthomonadales, pink shows members of the Pseudomonadales, and green shows members of the Enterobacteriales. At least four non-clonal isolates from each genus were tested with the exception of Salmonella (*), for which only one clinical isolate was obtained. Chequerboard data in a and b are representative of at least two biological replicates.
The increasing clinical use of polymyxins to treat multidrugresistant Gram-negative infections 1 , in combination with the global dissemination of plasmid-borne mcr-1, threatens the utility of these last-line antibiotics. Indeed, we observed resistance to colistin-a clinically revived polymyxin ( Supplementary Fig. 6a )-and to PMBN-dependent potentiation of rifampicin in E. coli expressing mcr-1 (Fig. 3a) . Notably, potentiation of rifampicin by pentamidine was retained upon expression of mcr-1 ( Fig. 3b and Supplementary  Fig. 6b ), suggesting that the action of pentamidine is independent of phosphoethanolamine (PEtN) modifications on lipid A. Significantly, these phenotypes persisted in two environmental E. coli isolates harbouring the mcr-1 gene on natural plasmids (Fig. 3c,d and Supplementary Fig. 6c ), and pentamidine retained adjuvant activity against Klebsiella pneumoniae expressing mcr-1 ( Supplementary Fig. 6d,e ).
The broad in vitro efficacy of pentamidine in combination with antibiotics typically restricted to Gram-positive bacteria suggested there is strong potential to repurpose pentamidine for antibacterial use. Importantly, exposure of wild-type E. coli to various combinations of pentamidine and rifampicin only generated mutants that displayed resistance to rifampicin (frequency of spontaneous resistance to rifampicin 4.2 × 10 −8 ; observed frequency of spontaneous resistance to pentamidine <8.3 × 10 −10 ; Supplementary  Table 6 ), suggesting that pentamidine may maintain clinical efficacy without the rapid development of resistance. Interestingly, the whole-cell antibacterial activity of pentamidine has been recognized for upwards of 70 years in the context of both Gram-positive 19, 24 and Gram-negative 19, 25, 26 bacteria, but this molecule has yet to be pursued as a modern clinical therapy, presumably due to insufficient potency in vitro. Indeed, with conventional knowledge suggesting . Treatment groups included 10 mg kg −1 pentamidine (pink, n = 10), 50 mg kg −1 novobiocin (green, n = 10) or a combination of 10 mg kg −1 pentamidine and 50 mg kg −1 novobiocin (blue, n = 11). Phenotypic endpoint was defined using a body condition score as described in the Methods. Experimental endpoint was defined as seven days post-infection. f, Bacterial load in the spleen was determined by selective plating on chloramphenicol. Black lines represent geometric mean of the bacterial load for each treatment group. Chequerboard data in a and d are representative of at least two biological replicates.
that the concentrations of pentamidine required for activity in vitro are beyond those that are clinically achievable in humans, there have been no compelling data to suggest that pentamidine would display therapeutic efficacy in vivo. Furthermore, early clinical studies of pentamidine reported numerous side effects, and only recently have advances been made to mitigate these risks 27 .
Recognizing the potential of dose-sparing drug combinations in therapy 28 , we tested the efficacy of pentamidine in combination with novobiocin in a systemic murine infection model of colistinsensitive A. baumannii (Fig. 4a) , an opportunistic pathogen capable of acquiring horizontally transferrable resistance determinants at high frequency 29 , and increasingly displaying colistin resistance in the clinic 30 . While pentamidine synergized with rifampicin against clinical isolates of A. baumannii ( Supplementary Table 4) , pentamidinedependent potentiation of novobiocin was considerably more potent, and as such this combination was selected for analysis of in vivo efficacy. Here, we observed 100% survival of mice treated with 10 mg kg −1 pentamidine in combination with 5 mg kg −1 novobiocin (Fig. 4b) . These doses represent just 1/5th and 1/20th of human equivalent therapeutic doses, respectively, highlighting a remarkable dose-sparing effect. Furthermore, the majority of mice treated with this combination contained no detectable A. baumannii in organ tissue at day 7 post-infection ( Fig. 4c and Supplementary  Fig. 7a-d) . Importantly, mice displayed organ occupancy of ∼1 × 10 6 c.f.u. ml −1 g −1 at time of treatment ( Supplementary Fig. 7e) , showing that combination therapy cured an established infection.
We next tested the efficacy of this combination of pentamidine and novobiocin in a systemic murine infection model of colistinresistant A. baumannii ( Fig. 4d and Supplementary Fig. 7f ). In this pathogen, the principal mechanism underlying colistin resistance is PEtN modification of lipid A, similar to that imparted by Mcr-1, and involves mutations in pmrAB (ref. 22) . Consistently, our colistin-resistant mutant displayed an A80V amino-acid substitution in PmrA. Here, co-administration of 10 mg kg −1 pentamidine and 50 mg kg −1 novobiocin rescued 10 of 11 infected mice, and resulted in total clearance of bacteria in the spleen (Fig. 4e,f ) . Interestingly, previous work has shown that colistin-resistant A. baumannii displays cross-resistance to host antimicrobial peptides 31 . Accordingly, our infection model may have required an elevated dose of novobiocin to aggressively halt infection given the diminished assistance of host innate immune factors.
The increasing incidence of spontaneous colistin resistance, as well as the acquisition of mcr-1 by alarmingly common pathogens such as carbapenem-resistant Enterobacteriaceae 32 , is resulting in the emergence of untreatable infections and threatens to overwhelm healthcare practices worldwide. Here, we highlight the utility of a powerful screening platform, and introduce a use for the antiprotozoal drug pentamidine as an antibiotic adjuvant for the treatment of polymyxin-resistant infections at subclinical doses in vivo. We posit that pentamidine and analogues thereof represent attractive leads as adjuvants to address the emerging threat of pan-resistant Gram-negative infections.
Methods
Genetic screening. The E. coli Keio collection 33 was pinned from frozen stocks at 1536-density onto solid Luria-Bertani (LB) medium using a Singer RoToR automated pinning system (Singer Instruments). Medium was supplemented with 64 µg ml −1 erythromycin, 128 µg ml −1 novobiocin, 8 μg ml −1 rifampicin or 32 µg ml −1 vancomycin. All antibiotics were purchased from Sigma-Aldrich. Cells were grown at 37°C for 18 h on LB containing erythromycin, novobiocin, or rifampicin, in duplicate. For low-temperature experiments, cells were grown at 15°C for 72 h on LB containing vancomycin, in duplicate. After incubation, plates were scanned in transmissive mode on an Epson Perfection V750-M scanner and quantitatively analysed using ImageJ. Plate images were background-subtracted using a 50-pixel rolling ball radius and converted to a binary image using the Otsu algorithm to identify colony margins. With colony margins identified, the integrated density (light absorption) of each was calculated as an indicator of cell number. Edge effects were corrected using a double-pass method across columns and rows based on the median value 34, 35 . Strains grown at 37°C in the presence of erythromycin, novobiocin or rifampicin with growth at least 3σ (standard deviations) less than the mean were defined as sensitive. Strains grown at 15°C in the presence of vancomycin with growth at least 3σ greater than the mean were defined as resistant. Genetic intersections between the various treatments were identified with the R statistical programming language 36 , and used to generate a four-treatment Venn diagram. From the vancomycin-resistant genetic subset of 41 strains, gene ontology (GO) terms were generated using EcoCyc pathway tools [37] [38] [39] . This list was further refined to include transcriptional regulation and biosynthetic pathways using an enrichment analysis in EcoCyc pathway tools. Counts of the number of genes present for each GO, biosynthetic pathway or promoter activation classification were compiled, along with P values, to assess statistical enrichment of cellular processes. ImageJ analyses for genetic screens were conducted using a recorded ImageJ macro. The Venn diagram generated using the R statistical programming language was calculated using the 'intersect' function.
Chemical screening. E. coli BW25113 was grown overnight in LB medium and diluted 1/5,000 into fresh LB containing 16 µg ml −1 vancomycin. A 49.5 µl volume of cells was subsequently transferred to each well of a clear 384-well flat-bottom plate (Corning) using a Beckman Coulter Biomek FX P laboratory automated workstation. A 0.5 µl volume of each molecule from a library of 1,440 previously approved drugs was added to cells using a 96-head pin tool (V&P Scientific), in duplicate, such that the final screening concentration of each compound was 10 µM. Plates were immediately read at 600 nm using a Perkin Elmer EnVision plate reader, then grown without shaking at 15°C for 96 h. Plates were again read at 600 nm, and cell growth was calculated by subtracting the initial optical density (OD) of each well at time 0 from the final OD at 96 h.
Chequerboard analyses. E. coli BW25113 was grown overnight in LB medium and diluted 1/5,000 into fresh LB. Vancomycin antagonism was determined by conducting standard chequerboard broth microdilution assays with eight twofold serially diluted concentrations of pentamidine (Sigma-Aldrich) and vancomycin against cells in a final volume of 100 µl. Plates were incubated without shaking at 15°C for 96 h before reading at 600 nm. This duration was sufficient for untreated cultures to reach early-stationary phase. Antibiotic synergy was determined by diluting overnight cultures 1/10,000 into fresh LB and conducting chequerboard broth microdilution assays with eight twofold serially diluted concentrations of various antibiotics in final volumes of 100 µl. Plates were incubated at 37°C with continuous shaking in a Tecan Sunrise plate reader (Tecan), with reads at 600 nm taken every 10 min to monitor growth. At early-stationary phase for each strain, experiments were halted and final reads were used to generate chequerboard plots. For polymyxin-resistant strains, overnight cultures were grown in the presence of 50 µg ml −1 kanamycin (for E. coli BW25113 and K. pneumoniae ATCC 43816 transformed with pGDP2:mcr-1) or 2 µg ml −1 colistin (for E. coli strains carrying mcr-1 on natural plasmids and the spontaneous colistin-resistant variant of A. baumannii ATCC 17978). The sequence of the pGDP2:mcr-1 plasmid has been deposited to GenBank under accession no. KX859085. Core OS mutants used to analyse pentamidine-dependent rifampicin potentiation were gathered from the E. coli Keio collection, except for the ΔwaaC strain, which was engineered in wild-type E. coli BW25113 using standard E. coli gene deletion techniques. Clinical isolates were curated from the Wright Clinical Collection. Isolation of the spontaneous colistin-resistant A. baumannii variant was conducted by plating the colistin-sensitive A. baumannii ATCC 17978 parent strain on 4 µg ml −1 colistin at 37°C for 48 h, and subsequent purification of a single colony. Whole-genome sequencing on an Illumina HiSeq platform revealed a point mutation in the pmrA gene, resulting in an A80V amino-acid substitution in the N-terminal receiver domain. Pentamidine analogues were purchased from WuXi AppTech. LPS purified from E. coli 0127:B8 (Sigma-Aldrich) or MgCl 2 (Sigma-Aldrich) was used in synergy inhibition experiments. Fractional inhibitory concentration (FIC) indices 40 Antibiotic potency analyses. Cells were grown overnight in LB medium, with or without selection as described above, and diluted 1/10,000 into fresh LB. Cells were then introduced to twofold serial dilutions of antibiotic in a final volume of 100 µl. Plates were incubated at 37°C with continuous shaking in a Tecan Sunrise plate reader, with reads at 600 nm taken every 10 min to monitor growth. At early-stationary phase for each strain, experiments were halted, and final reads were used to generate antibiotic potency plots. A conservative clinical MIC breakpoint for colistin of 2 µg ml −1 was set by the Société Française de Microbiologie 41 , and used to outline resistance in this study.
AFM sample preparation and imaging. Antibiotic treatments were prepared against E. coli BW25113 as described for antibiotic potency experiments. A 50 µl volume of mid-log culture (OD of ∼0.5) was transferred to hydrophilic polycarbonate 0.2 µm Millipore Isopore GTTP filters (Merck Millipore) on top of Kimwipes (Kimberly-Clark Professional) to absorb excess liquid across the filter.
A 50 µl volume of 25 mM HEPES pH 7.0 was then passed over the culture and absorbed by a Kimwipe to flush extracellular salts from the LB medium. Once the liquid had been removed, the filter was quickly attached to a clean glass slide with a non-conductive double-sided adhesive tab. Samples were imaged using a Bruker BioScope Catalyst (Bruker), with a Nanoscope V controller. For each treatment, a 0.65-µm-thick Si 3 N 4 triangular cantilever was used (Scan Asyst AIR, Bruker), with a symmetric tip and spring constant of ∼0.4 N m −1 . Scans were acquired at 25°C, with scan rates of 0.5 Hz and 512 samples per line resolution, in PeakForce quantitative nanomechanical mapping mode. Downstream image processing and analysis were performed using NanoScope software (Bruker). Height images were flattened to compensate for cell curvature, and topographical sections were used to generate two-and three-dimensional reconstructions of surface texture.
Outer membrane analyses. Cultures (20 ml) of E. coli BW25113 were grown at 37°C in LB containing various antibiotics until mid-log phase (OD of ∼0.5). For cell-surface LPS analysis, the equivalent of 1 ml of cells at OD = 1.0 were boiled in SDS-PAGE loading buffer for 10 min, and subsequently treated with proteinase K at 55°C for 3 h. The LPS core OS bands were then resolved on NuPAGE Novex 4-12% Bis-Tris gradient gels (Life Technologies), and visualized by silver staining. For LPS shedding, the remainder of each culture was centrifuged at 5,000g for 15 min at 4°C, and 10 ml of each supernatant was dialysed against water at 4°C for 24 h in dialysis tubing (Spectra/Por MWCO 3.5 kDa). The dialysed supernatants were lyophilized, resuspended in 200 µl water (1/50th of original volume), and then normalized according to culture OD at collection. Samples were boiled in SDS-PAGE loading buffer for 10 min, and subsequently treated with proteinase K at 55°C for 3 h. The LPS core OS bands were then resolved on NuPAGE Novex 4-12% Bis-Tris gradient gels, and visualized by silver staining. For membrane leakage analyses, concentrated supernatant samples were resolved on 12% SDS-PAGE gels and transferred into nitrocellulose membranes. After blocking in 5% skim milk in tris-buffered saline with Tween 20 (TTBS) for 2 h, membranes were incubated with anti-maltose binding protein antibody (New England Biolabs) diluted 1/10,000 or anti-RNA polymerase alpha subunit antibody (BioLegend; 1/3,000 dilution) overnight at 4°C. Membranes were washed in TTBS, and incubated with alkaline phosphatase-conjugated antimouse antibody (1/3,000) in 3% BSA in TTBS for 2 h. Membranes were again washed in TTBS and visualized with 5-bromo-4-chloro-3′-indolylphosphate p-toluidine salt (BCIP)/nitro-blue tetrazolium chloride (NBT). For periplasmic shock treatment, E. coli BW25113 was grown at 37°C in LB to an OD of ∼1.0, and cells were collected by centrifugation at 5,000g for 15 min at 4°C. Cells were resuspended in 3.5 ml buffer containing 100 mM Tris-HCl pH 8.0 + 500 mM sucrose, and incubated on ice for 5 min. Lysozyme was added to 100 µg ml −1 + 1 mM EDTA pH 8.0, and incubated on ice for 20 min. MgSO 4 was added to a final concentration of 20 mM, and the periplasmic fraction was collected by centrifugation at 12,000g for 10 min at 4°C.
Quantitative reverse transcription (qRT)-PCR. Wild-type E. coli BW25113 and E. coli BW25113 ΔphoP were grown overnight in LB medium and diluted 1/5,000 into 10 ml fresh LB supplemented with antibiotics as described. Cells were grown to mid-log phase (OD of ∼0.5) at 37°C and pelleted by centrifugation. Cells were then lysed in 2 ml TRIzol (Life Technologies) and incubated at room temperature for 5 min, or frozen at −20°C for later processing. Phase separation was performed by phenol-chloroform extraction. Chloroform (200 µl, Biobasic) was vigorously mixed with 1 ml TRIzol, followed by centrifugation at 12,000g for 15 min at 4°C. The aqueous phase was collected, and RNA was isolated by isopropanol-ethanol extraction. The aqueous phase was mixed with 500 µl of 100% isopropanol (Biobasic) per 1 ml of TRIzol reagent. After incubation at room temperature for 10 min, RNA was pelleted by centrifugation at 12,000g for 15 min at 4°C. RNA was then washed with 75% ethanol and centrifuged once more under the same conditions. The resulting pellet was allowed to air dry for 10 min to remove any remaining ethanol, and resuspended in 100 µl of RNase free water (Ambion). RNA was subject to DNase I treatment (Ambion) for 30 min at 37°C, followed by DNase inactivation. The RNA was then re-purified from DNase I by a subsequent isopropanol-ethanol wash step. RNA was mixed with isopropanol at −20°C for 30 min, pelleted by centrifugation, washed once with 75% ethanol, repelleted, and resuspended in water. Before cDNA synthesis, RNA from all isolates was adjusted to identical concentrations. Total RNA (600 ng) from each sample was used for reverse transcription using the Quanta Biosciences qScript cDNA supermix (Quanta Biosciences), as well as for a no RT control. First strand cDNA was diluted 1/10 prior to qRT-PCR, which was conducted in 96-well format using the Light cycler 480 (Roche) with SYBR Green (PerfeCTa SYBR green supermix, Quanta Biosciences). Primers JS02F and JS02R were used to amplify mgtA, which is upregulated in response to PhoPQ activation 42 , and JS03F and JS03R were used to amplify the housekeeping gene rsmC. Cycle threshold values were used to calculate RNA concentrations based on a standard curve for each primer pair. RNA concentrations for mgtA were then normalized to the RNA concentrations of rsmC. Experiments were conducted in technical and biological duplicates. JS02F-5′ cggtggtagtggcagaaaat3′; JS02R-5′gtctcttttggcggatcaag3′; JS03F-5′ gaaattctggggcgaataca3′; JS03R-5′ctttcacctcggaaaagacg3′.
Pentamidine frequency of resistance analysis. E. coli BW25113 was grown overnight in LB medium and concentrated to ∼1 × 10 9 c.f.u. ml −1 in fresh LB. A 100 µl volume of cells was then transferred onto solid LB in 100 mm Petri dishes (Fisher Scientific) supplemented with pentamidine and rifampicin as described.
The final number of cells deposited onto each plate was 1.1 × 10 8 c.f.u. ml −1 , as determined by serial plating onto non-selective LB. Cells were incubated at 37°C for 24 h, and single colonies from each condition were isolated and re-streaked onto fresh LB plates containing the pentamidine/rifampicin combination from which each suppressor emerged. After a subsequent incubation at 37°C for 24 h, reconfirming suppressors were grown in LB medium overnight, and tested for rifampicin sensitivity as described for antibiotic potency experiments. After observing that all 61 reconfirming suppressor mutants displayed resistance to rifampicin, a representative selection of isolates was then tested for possible crossresistance to pentamidine using chequerboard analyses at 37°C with pentamidine and novobiocin. All strains maintained pentamidine sensitivity. The observed frequency of resistance to pentamidine was then calculated as <1 11 × 1.1 × 10 8 < 8.3 × 10 −10 based on the total number of pentamidine/rifampicin combinations (11 conditions, 1.1 × 10 8 c.f.u. per condition) that displayed growth inhibition of E. coli. Using this calculation (61 suppressors, 13 conditions, 1.1 × 10 8 c.f.u. per condition), the frequency of resistance to rifampicin was calculated at 4.2 × 10 −8 , consistent with previous investigations 43, 44 .
Mouse infection models. Animal experiments were conducted according to guidelines set by the Canadian Council on Animal Care using protocols approved by the Animal Review Ethics Board at McMaster University under Animal Use Protocol #13-07-20. Sample size was selected based on the results of a preliminary infection trial (n = 3). Before infection, mice were relocated at random from a housing cage to treatment or control cages. No animals were excluded from analyses, and blinding was considered unnecessary. Seven-to nine-week-old female C57BL/6 mice (Taconic Biosciences) were infected intraperitoneally with ∼2 × 10 6 c.f.u. colistin-sensitive A. baumannii ATCC 17978, or the spontaneous colistin-resistant variant of A. baumannii ATCC 17978, with 5% porcine mucin (Sigma-Aldrich). Infections were allowed to establish for 2 h, and treatments were administered intraperitoneally as described. Clinical endpoint was determined using a five-point body condition score analysing weight loss, decrease in body temperature, respiratory distress, hampered mobility and hunched posture. Experimental endpoint was defined as seven days post-infection for mice not reaching clinical endpoint. Mice were euthanized and tissues were collected into ice-cold phosphate buffered saline (PBS) at necropsy. Blood was collected into sterile 2 ml heparinized tubes (BD Scientific). Organs were homogenized using a high-throughput tissue homogenizer (Retsch), serially diluted in PBS, and plated onto solid LB supplemented with 20 µg ml −1 chloramphenicol. Plates were incubated overnight at 37°C and colonies were quantified to determine organ load.
Data availability. Large screening data sets are provided in the Supplementary Information. The sequence of the pGDP2:mcr-1 plasmid has been deposited at GenBank under accession no. KX859085. Additional data that support the findings of this study are available from the corresponding author upon request.
